297 results on '"Rajkumar, S V"'
Search Results
2. Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design
3. N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression
4. Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design
5. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category
6. Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival
7. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression
8. Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents
9. Natural history of t(11;14) multiple myeloma
10. Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma
11. Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma
12. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy
13. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma
14. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the National Health and Nutritional Examination Survey
15. Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma
16. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
17. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
18. Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma
19. Clarification of the definition of complete response in multiple myeloma
20. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy
21. Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma
22. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma
23. Treatment patterns and outcomes in elderly patients with multiple myeloma
24. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma
25. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma
26. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project
27. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma
28. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS
29. Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategies
30. Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites
31. Management of treatment-emergent peripheral neuropathy in multiple myeloma
32. MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma
33. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
34. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis
35. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
36. Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma
37. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
38. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
39. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
40. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma
41. The current status of minimal residual disease assessment in myeloma
42. Treatment of newly diagnosed myeloma
43. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
44. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
45. Clinical and biological significance of RAS mutations in multiple myeloma
46. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system
47. The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement
48. Treatment of plasma cell dyscrasias with lenalidomide
49. Genetic aberrations and survival in plasma cell leukemia
50. Clinically relevant end points and new drug approvals for myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.